Drugs / Oxypurinol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00102271 | Jan 2005 → Apr 2011 | — | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1 | NCT00072826 | Nov 2003 → Aug 2007 | sickle cell disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00063687 | Mar 2003 → Jun 2005 | congestive heart failure | Advanz Pharma | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxypurinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00102271 ↗ |
| Known as | NSC-76239 | ChEMBL registry synonym — accepted as the source's own label CHEMBL859 ↗ |
| Known as | Oxipurinol | ChEMBL registry synonym — accepted as the source's own label CHEMBL859 ↗ |
| Action | Inhibit | “a xanthine oxidase (XO) inhibitor, oxypurinol” PMID 18549913 ↗ Jun 20081“Xanthine dehydrogenase inhibitor” CHEMBL859 ↗ |
| Modality | Small molecule | — CHEMBL859 ↗ |
| Route | Oral | “oral oxypurinol” NCT00063687 ↗ |
| Target | XDH | “Xanthine dehydrogenase inhibitor” CHEMBL859 ↗ |